Marc David
About
Marc David is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Radiation.
According to data from OpenAlex, Marc David has authored 49 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Pulmonary and Respiratory Medicine, 15 papers in Surgery and 11 papers in Radiation. Recurrent topics in Marc David's work include Prostate Cancer Diagnosis and Treatment (17 papers), Prostate Cancer Treatment and Research (12 papers) and Advanced Radiotherapy Techniques (11 papers). Marc David is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (17 papers), Prostate Cancer Treatment and Research (12 papers) and Advanced Radiotherapy Techniques (11 papers). Marc David collaborates with scholars based in Canada, France and Denmark. Marc David's co-authors include G Contesso, Jacques Rouëssé, M Trojani, J.‐F. Goussot, C Lagarde, F. Bonichon, N.B. Bui, Jean‐Michel Coindre, A. de Mascarel and Nguyen Binh Bui and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.
In The Last Decade
Marc David
46 papers receiving 1.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Marc David Canada | 17 | 1.5k | 809 | 449 | 417 | 337 | 49 | 1.9k | ||
| Thomas F. DeLaney United States | 14 | 1.8k 1.2× | 1.2k 1.4× | 429 1.0× | 660 1.6× | 492 1.5× | 22 | 2.0k | ||
| S. Taïeb France | 19 | 879 0.6× | 699 0.9× | 434 1.0× | 242 0.6× | 306 0.9× | 130 | 1.6k | ||
| Andrew J. Bishop United States | 26 | 1.1k 0.7× | 623 0.8× | 338 0.8× | 292 0.7× | 850 2.5× | 124 | 2.2k | ||
| Falk Roeder Germany | 30 | 1.5k 1.0× | 992 1.2× | 225 0.5× | 450 1.1× | 675 2.0× | 114 | 2.4k | ||
| Michèle Kind France | 24 | 1.3k 0.9× | 674 0.8× | 220 0.5× | 549 1.3× | 315 0.9× | 111 | 2.1k | ||
| Martin Robinson United Kingdom | 19 | 812 0.5× | 818 1.0× | 122 0.3× | 189 0.5× | 327 1.0× | 56 | 1.7k | ||
| Luu Tran United States | 20 | 905 0.6× | 1.0k 1.3× | 424 0.9× | 210 0.5× | 551 1.6× | 30 | 1.7k | ||
| Rudolf Schwarz Germany | 14 | 1.1k 0.7× | 413 0.5× | 149 0.3× | 427 1.0× | 562 1.7× | 46 | 1.8k | ||
| Deborah A. Frassica United States | 22 | 749 0.5× | 687 0.8× | 107 0.2× | 345 0.8× | 656 1.9× | 48 | 1.6k | ||
| Rick L. Haas Netherlands | 33 | 2.5k 1.7× | 1.5k 1.8× | 814 1.8× | 868 2.1× | 525 1.6× | 114 | 3.4k |
Countries citing papers authored by Marc David
Since
Specialization
Citations
This map shows the geographic impact of Marc David's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc David with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc David more than expected).
Fields of papers citing papers by Marc David
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Marc David. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc David. The network helps show where Marc David may publish in the future.
Co-authorship network of co-authors of Marc David
This figure shows the co-authorship network connecting the top 25 collaborators of Marc David. A scholar is included among the top collaborators of Marc David based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc David. Marc David is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
David, Marc, et al.. (2024). Atypical fractures of the lower extremities in two patients with rheumatoid arthritis: clinical presentations of presumed methotrexate osteopathy. BMJ Case Reports. 17(8). e256567–e256567.
2.
Tankel, James, Jonathan Spicer, Sara Najmeh, et al.. (2024). Survival in esophageal cancer with nonregional lymphadenopathy: a propensity score–matched analysis. Journal of Gastrointestinal Surgery. 28(6). 916–922.
3.
Skamene, Sonia, et al.. (2023). A Scalable Radiomics- and Natural Language Processing–Based Machine Learning Pipeline to Distinguish Between Painful and Painless Thoracic Spinal Bone Metastases: Retrospective Algorithm Development and Validation Study. SHILAP Revista de lepidopterología. 2. e44779–e44779.
4.
Skamene, Sonia, et al.. (2022). Radiomics-based machine learning models to distinguish between metastatic and healthy bone using lesion-center-based geometric regions of interest. Scientific Reports. 12(1). 9866–9866.
5.
Tsui, James Man Git, Mame Daro Faye, Christine Lambert, et al.. (2021). Extreme weekly locoregional hypofractionated radiation in elderly women with non-metastatic breast cancer. Radiotherapy and Oncology. 162. 156–161.
6.
Sudarshan, Monisha, Thierry Alcindor, Steven Ades, et al.. (2014). Survival and Recurrence Patterns after Neoadjuvant Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) for Locally Advanced Esophagogastric Adenocarcinoma. Annals of Surgical Oncology. 22(1). 324–330.
7.
Patel, Nita, Luís Souhami, José João Mansure, et al.. (2014). Prostate-specific antigen bounce after high-dose-rate prostate brachytherapy and hypofractionated external beam radiotherapy. Brachytherapy. 13(5). 450–455.
8.
Patel, Nita, Sergio Faria, Fabio Cury, et al.. (2013). Hypofractionated Radiation Therapy (66 Gy in 22 Fractions at 3 Gy per Fraction) for Favorable-Risk Prostate Cancer: Long-term Outcomes. International Journal of Radiation Oncology*Biology*Physics. 86(3). 534–539.
9.
Niazi, Tamim, T. Vuong, Laurent Azoulay, et al.. (2012). Silver Clear Nylon Dressing is Effective in Preventing Radiation-Induced Dermatitis in Patients With Lower Gastrointestinal Cancer: Results From a Phase III Study. International Journal of Radiation Oncology*Biology*Physics. 84(3). e305–e310.
10.
Hanna, Waël C., Monisha Sudarshan, David Roberge, et al.. (2012). What Is the Optimal Management of Dysphagia in Metastatic Esophageal Cancer?. Current Oncology. 19(2). 60–66.
11.
Faria, Sergio, Alan Dal Pra, Fabio Cury, et al.. (2011). Treating intermediate-risk prostate cancer with hypofractionated external beam radiotherapy alone. Radiotherapy and Oncology. 101(3). 486–489.
12.
Wong, Philip, Christine Lambert, Ramanakumar V. Agnihotram, et al.. (2011). Ductal Carcinoma in Situ—The Influence of the Radiotherapy Boost on Local Control. International Journal of Radiation Oncology*Biology*Physics. 82(2). e153–e158.
13.
Faria, Sergio, Fabio Cury, Marc David, et al.. (2010). Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 77(3). 805–810.
14.
Bethke, T.D., Thomas Gießmann, Kristin Westphal, et al.. (2006). Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects. International Journal of Clinical Pharmacology and Therapeutics. 44(11). 572–579.
15.
Faria, Sergio, Salaheddin M. Mahmud, Luís Souhami, et al.. (2006). No immediate treatment after biochemical failure in patients with prostate cancer treated by external beam radiotherapy. Urology. 67(1). 142–146.
16.
Cury, Fabio, Luís Souhami, Raghu Rajan, et al.. (2005). Intermittent androgen ablation in patients with biochemical failure after pelvic radiotherapy for localized prostate cancer. International Journal of Radiation Oncology*Biology*Physics. 64(3). 842–848.
17.
Vuong, T., Peter Szego, Marc David, et al.. (2005). The safety and usefulness of high-dose-rate endoluminal brachytherapy as a boost in the treatment of patients with esophageal cancer with external beam radiation with or without chemotherapy. International Journal of Radiation Oncology*Biology*Physics. 63(3). 758–764.
18.
Degardin, M., Jean Pierre Armand, Bernard Chevallier, et al.. (1995). A Clinical Screening Cooperative Group phase II evaluation of lobaplatin (ASTA D-19466) in advanced head and neck cancer. Investigational New Drugs. 13(3). 253–255.
19.
Robert, Jacques, Marc David, Sylvie Huet, & J Chauvergne. (1988). Pharmacokinetics and metabolism of pirarubicin in advanced cancer patients. European Journal of Cancer and Clinical Oncology. 24(8). 1289–1294.
20.
Constans, J P, et al.. (1956). Recherche des critères d'indication opératoire dans les anévrismes artério-veineux cérébraux.. Neurochirurgie. 2(3).
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Thomas F. DeLaney Breakdown of academic impact, for papers by S. Taïeb Breakdown of academic impact, for papers by Andrew J. Bishop Breakdown of academic impact, for papers by Falk Roeder Breakdown of academic impact, for papers by Michèle Kind Breakdown of academic impact, for papers by Martin Robinson Breakdown of academic impact, for papers by Luu Tran Breakdown of academic impact, for papers by Rudolf Schwarz Breakdown of academic impact, for papers by Deborah A. Frassica Breakdown of academic impact, for papers by Rick L. Haas